Tang et al. have reported that GALK1 might be a new target for treating hepatocellular carcinoma (HCC) and also revealed that galactose metabolic pathway exhibited a new posttranscriptional regulation effect on the protein expression of PI3K/AKT signaling pathway in HCC [31]. The gene discussed is GALK1; the disease is hepatocellular carcinoma.